Previous Close | 0.0376 |
Open | 0.0376 |
Bid | 0.0376 x N/A |
Ask | 0.0600 x N/A |
Day's Range | 0.0376 - 0.0376 |
52 Week Range | 0.0160 - 0.1890 |
Volume | |
Avg. Volume | 972 |
Market Cap | 4.265M |
Beta (5Y Monthly) | 1.43 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0310 |
Earnings Date | Nov 29, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for 8SV1.F
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences (“WFUHS”). On April 22, 2022 WPD Pharmaceuticals Sp. z o.o. (“WPD Poland”), the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2, WPD signed An
Expert research team aiming to optimize the effects of radiotherapy of brain tumorsVANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project. The consortium will research the potential of AGuIX® nanoparticles in maximizing radiotherapy efficiency a
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”) has approved a plan to restructure (the “Restructuring”) the outstanding capitalization of the Company’s wholly owned Polish subsidiary WPD Pharmaceuticals sp. z.o.o. (“WPD Poland”). Due to the occurrence of negative shareholders’ equity in WPD Poland, under Polish corporate law, WPD Poland is obliga